COMP <GO>
ODTX vs GLUE // GROSS PROFIT MARGIN
Odyssey Therapeutics Inc. (NASDAQ) VS. Monte Rosa Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ODTX 2
— GLUE 0
■ METRIC PARITY
LAST: $19.83 (+1.48%) • MKT CAP: $953.0M
gross-margins
—
LAST: $10.87 (+0.18%) • MKT CAP: $927.4M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ODTX VS. GLUE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ODTX | GLUE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.9 | 44.6 | +4.29 | ODTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $953.0M | $927.4M | $25.6M | ODTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ODTX REV | GLUE REV | ODTX GROSS % | GLUE GROSS % | ODTX FCF | GLUE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | — | -$27.5M |
| FY 2024 | — | $0 | — | — | — | $38.0M |
| FY 2023 | — | $0 | — | — | — | -$43.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ODTX // BETA —
GLUE // BETA —